GSK appoints Kevin Sin as new SVP and Head of Worldwide Business Development for R&D
Critical role appointed as part of ongoing activities to strengthen and accelerate the Pharmaceuticals pipeline
Issued: London, UK
GlaxoSmithKline plc (GSK) today announced the appointment of Kevin Sin as Senior Vice President and Head of Worldwide Business Development for Pharmaceuticals Research & Development. In this position, Kevin will play a critical role in strengthening GSK’s pharmaceutical pipeline and identifying enabling technologies to enhance delivery of innovative new medicines for patients.
Kevin will join GSK in July from Genentech, where he is currently Vice President and Global Head of Oncology Business Development, responsible for partnering, acquisition and licensing activities for novel oncology therapeutics. He has worked within the pharmaceutical and life sciences industry for over 20 years in roles spanning business development, legal and research. Prior to joining Genentech in 2006, Kevin was an attorney advising private and public life sciences companies on business development and strategic partnering transactions. He began his career as a scientist. Kevin holds a B.A. in Molecular and Cell Biology from the University of California, Berkeley and a post graduate degree (Juris Doctor) from the University of San Francisco School of Law.
Dr. Hal Barron, Chief Scientific Officer and President of Research and Development, GSK, commented: “I am extremely excited to have Kevin join GSK. Gaining access to the best science and technologies across the world as well as establishing highly productive collaborations with academia and industry, play an important role in creating a world-class R&D organization. Kevin’s leadership skills, significant expertise and successful track record make him the ideal person to lead Business Development activities for R&D.”
Kevin Sin commented: “I am thrilled to be joining GSK at such an exciting time and important stage of the company’s growth. The incredible pace of scientific and technical innovation that is happening around the world is significant and presents an abundance of opportunities to combine GSK’s strengths and capabilities with that of others to pursue big ideas in science and medicine. I look forward to working with the team to explore collaborations that can accelerate the discovery and development of new medicines with the potential to significantly improve human health.”
Kevin will report to Hal Barron and be based in San Francisco.
GSK - a science-led global healthcare company with a special purpose: to help people do more, feel better, live longer. For further information please visit www.gsk.com/en-gb/about-us
GSK cautionary statement regarding forward-looking statements
GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Such factors include, but are not limited to, those described under Item 3.D 'Principal risks and uncertainties' in the company's Annual Report on Form 20-F for 2017.